Background: Preoperative chemotherapy (PCT) allows for in vivo testing of treatment effects on tumor and its microenvironment. Aim of this analysis was to evaluate the effect of PCT on tumor biomarker expression and to evaluate the prognostic role of treatment-induced variation of these biomarkers (molecular response).
introduction
Preoperative chemotherapy (PCT) is the standard of care for large primaries and inflammatory breast cancer and is increasingly used also in earlier stages of the disease. Besides its proven advantage in increasing the rate of breast-conserving surgery (BCS), this strategy allows for an in vivo assessment of treatment efficacy: in fact, the response achieved on the primary tumor is a strong predictor of outcome [1] [2] [3] . In particular, patients achieving a pathological complete response (pCR), irrespectively of the initial stage and molecular subtype, have a very low risk of relapse. On the other hand, the patients with residual disease in the breast and/or axilla represent a heterogeneous group with very different risks of relapse. Available data indicate that persistent nodal disease is an unfavorable prognostic parameter [4, 5] ; however, even this group includes patients where PST has induced an important downstaging as well as patients with highly resistant disease. It is therefore clear that the classification of responses to PCT in pCR versus non-pCR is a useful prognostic indicator for those patients with pCR, but it oversimplifies the different prognostic categories for the patients with less pCR. Many studies have shown that high proliferation, absence of hormone receptor expression, poor differentiation, and human epidermal growth factor receptor 2 (HER2) overexpression are prognostic markers as well as markers of treatment sensitivity, and these biomarkers have been associated with higher probability of obtaining a pCR [3, [6] [7] [8] . On the other side, in patients with less pCR, these biomarkers can be measured again and the variation in expression induced by PCT might have prognostic significance. It has been shown that higher expression of Ki-67 after 2 weeks of preoperative endocrine therapy was significantly associated with shorter progression-free survival, while higher levels at baseline were not [9] . In patients treated with PCT, both pre-and post-therapy Ki-67 were significant predictors of overall survival (OS), but post-PCT had a stronger prognostic impact [10] . Moreover, we had previously reported that high values of thymidine-labeling index in residual tumor after PCT in locally advanced breast cancer were associated with a higher risk of relapse [11] .
Aim of this analysis was to evaluate the effect of chemotherapy on the expression of markers of tumor proliferation, angiogenesis, apoptosis, and their potential prognostic implication in patients with residual disease following PCT.
methods patient selection
Prospectively collected data from 221 consecutive patients with clinical stage II-III breast cancer treated with PCT were evaluated. At diagnosis, patients underwent complete workout staging to exclude distant metastases, including chest-XR, abdominal ultrasonography, and bone scan for patients with clinically enlarged axillary lymph nodes. The local extent of the disease was evaluated by mammography, breast ultrasonography, and clinically by caliper. Patient characteristics including clinical stage, type of primary systemic chemotherapy, type of surgery, and pathologically documented response in breast and axilla were recorded.
pathology
Breast cancer diagnosis was made by needle biopsy of the breast tumor. All pathological specimens were evaluated by dedicated breast pathologists.
The following parameters were evaluated on specimens from both biopsy and surgery: histological type, histological grade, estrogen receptor (ER), progesterone receptor (PgR), HER2, proliferation index (Ki-67), apoptotic index (TUNEL assay), p53, human epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 2 (VEGFR2) (KDR/Flk1) expression.
The histological type was defined by using the World Health Organization's classification system. The histological grade was defined according to the Elston and Ellis classification grading system. 
assessment of the apoptotic index
The sections were stained for apoptosis using the TUNEL technique. Apoptotic cells were identified by the TUNEL method, according to the standard procedure included in the Apop Tag Plus In Situ Apoptosis Detection Kit (Chemicon International, Temecula, CA, USA). The apoptotic index (AI) was defined as the percentage of apoptotic events per cell population. The AI was assessed by counting at least 3000 malignant cells randomly selected at ·400 magnification. assessment of response pCR was defined as complete disappearance of invasive carcinoma in both breast and axillary lymph nodes. Residual ductal carcinoma in situ was included in the pCR category.
treatment and follow-up

statistical analysis
The association between baseline biomarker expression and pCR was assessed by using Pearson chi-square test. Treatment-induced biomarker variations were assessed by using t-test for paired data. Survival curves were estimated with the Kaplan-Meier method and the log-rank test was used to test for differences between groups. Disease-free survival (DFS) was calculated from the date of surgery to the date of disease relapse (local or distant), death from any cause, or last follow-up. OS was calculated from the date of diagnosis to the date of death or last follow-up. The survival estimates according to the biomarker expression after PCT have been calculated from date of surgery to the date of death or last follow-up. Level of significance was set to 0.05. Hazard Ratios (HRs) and their confidence intervals were estimated by using Cox model.
results patients and response
Two hundred and twenty-one stage II-III breast cancer patients treated with PCT were included; 216 patients underwent surgery: BCS was carried out in 45% of the patients, while 55% of the patients received mastectomy. Five patients did not receive surgery because of disease progression, refusal, or noncancer death. Patients' characteristics are listed in Table 1 .
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A pCR was observed in 8.8% of the patients: the probability of pCR was significantly higher in case of ER negativity, nuclear grade 3, HER2 positivity, and p53 >10% ( Table 2) . No relation between age and clinical stage at diagnosis and probability of obtaining a pCR was observed. Of the patients who underwent surgery, 197 had residual breast disease: 57% of the cases had residual disease <2 cm; 38% between 2 and 5 cm; and 5% had residual disease >5 cm. Thirty-five percent of the patients had no involved axillary nodes, 30% had one to three nodes, 19% four to nine nodes, and 16% had >10 involved nodes.
effect of PCT on tumor biomarker expression
PCT induced a reduction in the expression of tumor biomarkers as compared with baseline: ER by 38% (P < 0.0001), PgR by 20% (P < 0.0001), Ki-67 by 13% (P < 0.0001), EGFR by 2% (P = 0.06), apoptosis (TUNEL test) by 3% (P < 0.0001), VEGFR 2 by 6% (P = 0.06), and p53 expression was not modified by PCT.
expression of tumor biomarkers and survival
The survival estimates according to the expression of tumor biomarkers after PCT are summarized in Table 3 . In particular, patients with high Ki-67 expression ( ‡15%) following PCT experienced a significantly shorter DFS and OS as compared with patients with low Ki-67 expression (5-year DFS 50.2% versus 77.2%, P = 0.0001 and 5-year OS 73.1% versus 87.8%, P = 0.0078) (Figure 1) .
On the other hand, the baseline expression of Ki-67 was only marginally associated with DFS (5-year DFS 60.5% in patients with Ki-67 ‡15% versus 83.4% in patients with Ki-67 <15%, P = 0.048), and no correlation with OS was observed. All significant factors in the univariate analyses were included in the multivariable model: only Ki-67 and nodal status after PCT resulted significant predictors of survival. In particular, Ki-67 ‡15% and nodal positivity were associated with worse DFS (HR 3.75, P < 0.0001 and HR 2.31, P = 0.037, respectively); Ki-67 ‡15% after PCT was also a significant predictor of OS (HR 3.75, P = 0.013).
generation of a prognostic model
On the basis of these two parameters after PCT, patients were therefore classified into three groups-(i) low risk ( , and 43%, respectively (log-rank test P < 0.0001). As compared with the low-risk group, the HRs for recurrence were 3.1 and 9.3 for the intermediate-and high-risk group, respectively (P = 0.0001). Five-year OS rates were 86%, 88%, and 64%, respectively (log-rank test P = 0.035); as compared with the low-risk group, the HRs for death were 2.4 and 6.5 for the intermediate-and high-risk group, respectively (P = 0.042). Kaplan-Meier plot of DFS and OS according to the three risk groups is represented in Figure 2 . Because of its biological relevance, we decided to consider ER status in the Cox model, even though it was not statistically associated with recurrence of death. However, the inclusion of this parameter did not change the association between the three risk groups and recurrence or death. discussion PCT permits to increase the rate of BCS and allows to discriminate clearly at least two groups of patients: those who achieve a pCR with a very good outcome and patients with residual disease who are at higher risk of disease recurrence. However, the group of patients not in pCR is heterogeneous, including patients with highly resistant disease as well as patients where chemotherapy might have induced an important downstaging even in presence of metastatic nodes.
The identification of markers able to better discriminate different prognostic categories among this group of patients will allow to select patient candidates to additional postoperative treatments. In fact, apart from endocrine therapy in case of hormone receptor positive tumors, there are few data to support the administration of additional treatments after PCT. The experience from MD Anderson has shown a nonsignificant trend toward improved relapse-free survival and OS for sequential non-cross-resistant chemotherapy in patients with residual disease after four courses of an anthracycline-based combination [12] . However, this relatively old trial did not include taxanes, which are now usually incorporated in the PCT plan, and there is no evidence that any chemotherapy might add benefit in patients with less pCR after anthracycline-taxane-based PCT [13] .
It is therefore clear that a more refined prognostic classification could identify the optimal candidates to test the efficacy of new treatments.
The group from the MD Anderson Cancer Center has shown that the residual cancer burden (RCB), an index obtained combining pathological measurements of residual breast tumor (size and cellularity) and number and size of nodal metastases, is an independent predictor of distant relapse-free survival in 382 patients treated with PCT [14] . In particular, as compared with the American Joint Committee original article Annals of Oncology on Cancer stage groups [14] , the RCB allowed to discriminate subgroups at different prognosis in stage II or III disease.
More recently, the combination of clinical and pathological staging has been used to generate a scoring system to predict the 5-year prognosis after PCT [15] . This system is based on clinical stage, pathological stage, ER status, and nuclear grade and identifies seven distinct prognostic groups.
The aim of our analysis was to evaluate the effect of chemotherapy on the expression of markers of tumor proliferation, angiogenesis, apoptosis, and their potential prognostic implication in patients with less pCR after PCT.
As previously reported, the probability of obtaining a pCR was higher in case of ER negativity, HER2 positivity, and poorly differentiated tumors [3, [6] [7] [8] . In our series, the expression of mutated p53 was also a marker of chemosensitivity: the patients with high p53 expression were more likely to achieve a pCR. The predictive role of mutated, nonfunctional p53 in breast cancer is still controversial. Thor et al. have shown that p53 mutations were associated with sensitivity to higher dose of adjuvant doxorubicin, while Rozan et al. found no correlation between p53 mutation and response to chemotherapy or radiotherapy in the preoperative setting [17, 18] . More recently, von Minckwitz et al. found no correlation between p53 and response to preoperative dose-dense doxorubicin-docetaxel chemotherapy [19] . The different methodologies in p53 evaluation used in these and our study do not allow a direct comparison. Moreover, in our study, this marker was assessed in a subset of patients only; therefore this observation needs further assessment on larger series.
In patients with less pCR, PCT induced a reduction in the expression of tumor biomarkers as compared with baseline that was significant with respect to ER, PgR, Ki-67, and apoptosis. We observed that patients with high Ki-67 expression following PCT experienced a significantly shorter DFS and OS as compared with patients with low Ki-67 expression, while the baseline Ki-67 level was only marginally associated with DFS and not correlated with OS.
Tumor proliferation is a predictor of breast cancer prognosis [20, 21] . A recently published meta-analysis including 46 studies and 12 155 patients has shown that in early breast cancer, Ki-67/MIB-1 positivity confers a higher risk of relapse and a worse survival [22] .
In an analysis conducted on 1924 node-negative patients with hormone receptor-positive tumors entered into two randomized trials of endocrine therapy 6 chemotherapy, a high Ki-67-labeling index was an independent prognostic factor, but not predictive of the relative efficacy of adding chemotherapy to hormonal treatment [23] .
The group from Royal Marsden Hospital has tested the role of Ki-67 as potential marker of treatment effect in a subgroup of patients enrolled in the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen trial. They have reported that a higher Ki-67 expression after 2 weeks of preoperative endocrine therapy is a significant predictor of shorter recurrence-free survival [9] .
In our study, tumor proliferation as measured as Ki-67 expression was significantly reduced by chemotherapy. However, patients with high Ki-67 expression after PCT had significantly shorter DFS and OS. The expression of Ki-67 after PCT was found to be significant predictor of outcome independently by nodal status. On the contrary, baseline Ki-67 was only marginally related with DFS and no correlation with OS was observed. Therefore, we can assume that Ki-67 levels after PCT can be used as a surrogate marker of treatment efficacy. On the basis of the two factors significantly related with patient outcome in the multivariable model, we have generated a simple and easily reproducible prognostic model, able to discriminate patients with worse prognosis among the heterogeneous group of women with residual disease after PCT.
These data confirm that molecular response is an important surrogate marker of the efficacy of primary systemic therapy for operable disease. Moreover, in our hands, two parameters, nodal status and Ki-67 expression, easily allow clinicians to discriminate three groups of patients at clearly different risks of . Log-rank test: P = 0.042. Risk groups: low risk (Ki-67 < 15% and node negativity after PCT); intermediate risk (Ki-67 ‡ 15% or node positivity after PCT); and high risk (Ki-67 ‡ 15% and node positivity after PCT). Log-rank test: P < 0.0001. PCT = preoperative chemotherapy.
Annals of Oncology original article relapse after PCT. The low-risk group, encompassing 15% of the patients, has a DFS similar to that observed for pCR patients. On the contrary, the intermediate-risk group, including >50% of the patients, and the high-risk group, including 30% of the patients, have a relative risk of relapse of 3.1 and 9.3, respectively. Interestingly, these HRs have been observed in spite of the adjuvant endocrine therapies administered to the hormone receptor-positive tumors and definitively indicate that these patients need additional treatments.
In conclusion, the evaluation of molecular markers of response should be included in primary systemic treatment program and represents a further step toward a more customized treatment. 
